Emerging evidence for a multitude of mechanisms and factors that determine amphotericin B resistance in pathogenic fungi.

Anshu Chauhan, Neil A R Gow, Rajendra Prasad

Abstract readReview

In one paragraph

Review in Cell surface (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anshu ChauhanAmity Institute of Biotechnology, Amity University Gurugram, Haryana, India.

Neil A R GowMedical Research Council Centre for Medical Mycology at the University of Exeter University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, UK.

Rajendra PrasadAmity Institute of Biotechnology, Amity University Gurugram, Haryana, India.

Funding

Wellcome Trust

6 · The paper itself

Abstract

The fungicidal polyene amphotericin B (AMB) is the oldest antifungal for the treatment of systemic infections, and it remains a critical broad-spectrum therapeutic option, despite its well-documented nephrotoxicity. In many countries use of conventional amphotericin deoxycholate has been eclipsed by the introduction in the 1990s of the considerably more expensive but much less nephrotoxic lipid formulations. Amphotericin B is valued for its strong fungicidal activity at low doses and its rarity of resistance, as resistance usually carries a significant fitness cost for fungi. However, emerging pathogens such as

Indexed as

Alternative oxidaseAmphotericin BAntifungal drug resistanceSphingolipids

Identifiers

PMID41552396

DOI10.1016/j.tcsw.2026.100168

PMCPMC12811487

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.